Deliberate AI anxiety/depression model accepted into ISTAND
In a first, the U.S. FDA accepted an artificial intelligence (AI)/machine learning-model into its Innovative Science and Technology Approaches for New Drugs (ISTAND) pilot program for drug development. The program will support use of Deliberate AI Inc.’s anxiety and depression assessment tool, called the AI-generated Clinical Outcome Assessment (AI-COA), as a qualified drug development tool.
Ai Inc Technology Approaches For New Drugs Innovative Science Technology Approaches New Drugs Clinical Outcome Assessment
Source: bioworld.com